These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17043684)

  • 1. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo.
    Sato K; Yuasa T; Nogawa M; Kimura S; Segawa H; Yokota A; Maekawa T
    Br J Cancer; 2006 Nov; 95(10):1354-61. PubMed ID: 17043684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo.
    Yuasa T; Nogawa M; Kimura S; Yokota A; Sato K; Segawa H; Kuroda J; Maekawa T
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):853-9. PubMed ID: 15701876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice.
    Zhang H; Yano S; Miki T; Goto H; Kanematsu T; Muguruma H; Uehara H; Sone S
    Clin Exp Metastasis; 2003; 20(2):153-9. PubMed ID: 12705636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
    Inoue K; Karashima T; Fukata S; Nomura A; Kawada C; Kurabayashi A; Furihata M; Ohtsuki Y; Shuin T
    Clin Cancer Res; 2005 Sep; 11(18):6669-77. PubMed ID: 16166446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice.
    Yano S; Zhang H; Hanibuchi M; Miki T; Goto H; Uehara H; Sone S
    Clin Cancer Res; 2003 Nov; 9(14):5380-5. PubMed ID: 14614023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anti-leukemic efficacy of the third generation bisphosphonate ONO5920/YM529.
    Segawa H; Kimura S; Kuroda J; Sato K; Nogawa M; Yuasa T; Yokota A; Hodohara K; Fujiyama Y; Maekawa T
    Leuk Res; 2005 Apr; 29(4):451-7. PubMed ID: 15725480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination with third-generation bisphosphonate (YM529) and interferon-alpha can inhibit the progression of established bone renal cell carcinoma.
    Kurabayashi A; Inoue K; Fukuhara H; Karashima T; Fukata S; Kawada C; Shuin T; Furihata M
    Cancer Sci; 2015 Aug; 106(8):1092-9. PubMed ID: 26041278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.
    Koshimune R; Aoe M; Toyooka S; Hara F; Ouchida M; Tokumo M; Sano Y; Date H; Shimizu N
    BMC Cancer; 2007 Jan; 7():8. PubMed ID: 17222343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.
    Miwa S; Mizokami A; Keller ET; Taichman R; Zhang J; Namiki M
    Cancer Res; 2005 Oct; 65(19):8818-25. PubMed ID: 16204052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.
    Horie N; Murata H; Kimura S; Takeshita H; Sakabe T; Matsui T; Maekawa T; Kubo T; Fushiki S
    Br J Cancer; 2007 Jan; 96(2):255-61. PubMed ID: 17242698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bisphosphonate zoledronic acid effectively targets lung cancer cells by inhibition of protein prenylation.
    Xie F; Li P; Gong J; Zhang J; Ma J
    Biochem Biophys Res Commun; 2015 Nov; 467(4):664-9. PubMed ID: 26498526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microvascular endothelial cell responses in vitro and in vivo: modulation by zoledronic acid and paclitaxel?
    Michailidou M; Brown HK; Lefley DV; Evans A; Cross SS; Coleman RE; Brown NJ; Holen I
    J Vasc Res; 2010; 47(6):481-93. PubMed ID: 20431297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer.
    Yonou H; Ochiai A; Ashimine S; Maeda H; Horiguchi Y; Yoshioka K; Ogawa Y; Hatano T; Tachibana M
    Prostate; 2007 Jun; 67(9):999-1009. PubMed ID: 17440967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of mitochondria-dependent apoptosis through the inhibition of mevalonate pathway in human breast cancer cells by YM529, a new third generation bisphosphonate.
    Nakajima H; Magae J; Tsuruga M; Sakaguchi K; Fujiwara I; Mizuta M; Sawai K; Yamagishi H; Mizuta N
    Cancer Lett; 2007 Aug; 253(1):89-96. PubMed ID: 17316980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway.
    Tsubaki M; Satou T; Itoh T; Imano M; Ogaki M; Yanae M; Nishida S
    Toxicol Appl Pharmacol; 2012 Mar; 259(3):402-10. PubMed ID: 22326785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis-inducing effect of a new bisphosphonate, YM529, on various hematopoietic tumor cell lines.
    Nishida S; Kikuichi S; Haga H; Yoshioka S; Tsubaki M; Fujii K; Irimajiri K
    Biol Pharm Bull; 2003 Jan; 26(1):96-100. PubMed ID: 12520182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
    Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K
    Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits tumor metastasis in mouse melanoma through suppression of the Rho/ROCK pathway.
    Tanimori Y; Tsubaki M; Yamazoe Y; Satou T; Itoh T; Kidera Y; Yanae M; Yamamoto C; Kaneko J; Nishida S
    Clin Exp Metastasis; 2010 Oct; 27(7):529-38. PubMed ID: 20632074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells.
    Takahashi R; Shimazaki C; Inaba T; Okano A; Hatsuse M; Okamoto A; Hirai H; Ashihara E; Nakagawa M
    Leuk Res; 2001 Jan; 25(1):77-83. PubMed ID: 11137564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer.
    Hadaschik BA; ter Borg MG; Jackson J; Sowery RD; So AI; Burt HM; Gleave ME
    BJU Int; 2008 Jun; 101(11):1347-55. PubMed ID: 18384637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.